The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Dedifferentiated liposarcomas (DDLPS) exhibit resistance to conventional therapies, necessitating novel treatment approaches.
• Elevated Hepatocyte Growth Factor Receptor (Met) expression in DDLPS suggests its potential involvement in disease progression.
• The precise functional role of Met signaling in DDLPS remains largely uncharacterized.

Purpose of the Study:

• To investigate the functional role of Met signaling in DDLPS.
• To evaluate Met as a potential therapeutic target for DDLPS.
• To assess the efficacy of a Met-specific inhibitor in preclinical DDLPS models.

Main Methods:

• Stimulation of DDLPS cells with Hepatocyte Growth Factor (HGF) to assess pathway activation and phenotypic changes.
• Met knockdown using shRNA to evaluate the impact on DDLPS cell behavior in vitro and in vivo.
• Treatment of DDLPS xenografts with the Met inhibitor EMD1214063 to assess anti-tumor efficacy and survival.

Main Results:

• HGF stimulation enhanced PI3K/AKT and MAPK signaling, promoting DDLPS cell proliferation, invasion, and migration.
• Met knockdown abrogated HGF-induced pro-tumorigenic phenotypes and reduced DDLPS tumorigenicity in vivo.
• EMD1214063 inhibited Met signaling, reduced DDLPS oncogenicity, and significantly improved survival in mice with DDLPS xenografts.

Conclusions:

• Met signaling plays a critical pro-tumorigenic role in DDLPS.
• Targeting Met signaling represents a promising therapeutic strategy for DDLPS.
• Further investigation of Met inhibition for enhanced clinical outcomes in DDLPS is warranted.